TB-500 (Thymosin Beta-4) Not FDA-approved as a finished drug product, though clinical trials have used IV thymosin beta-4
13.3.5 Virulence trait expression and reversion risk Of particular concern in the safety evaluation of probiotics is their potential for virulence reversion, a risk that is markedly higher in strains of pathogenic origin, particularly under favorable environmental conditions
Chromatographic separation was conducted on a Brownlee SPP C18 column (2.1 mm 75 mm, 2.7 m particle size, Perkin Elmer, Waltham, MA) using mobile phase A (100% H2O containing 0.1% formic acid and 1% of 1 M NH 4 OAc) and B (1:1 acetonitrile:isopropanol containing 0.1% formic acid and 1% of 1 M NH 4 OAc)
Using a nasal spray eliminates the need for reconstitution, and dosing is straightforward with the metered spray format
Most published data comes from in vitro and animal studies